Trial Profile
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Molibresib (Primary)
- Indications Carcinoma; Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 09 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2018 New trial record